News
Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated ...
MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / ...
The keen interest from Big Pharma has also excited the stock market. After the Otsuka deal was announced, HBM's share price ...
Opinion: Legal scholar John Shu says a ban or restriction on direct-to-consumer drug advertisements would be illogical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results